News &

Media Contact

Amy Merves
Manager of
Media Relations



Fox Chase Cancer Center's V. Craig Jordan Elected to the American Association for Cancer Research Board of Directors

PHILADELPHIA (May 16, 2007) — V. Craig Jordan, OBE, PhD, DSc, vice president and research director for medical science at Fox Chase Cancer Center and Alfred G. Knudson Jr., MD, PhD, Chair in Cancer Research, has been elected to the American Association of Cancer Research (AACR) Board of Directors for the 2007-2010 term. The mission of AACR is to prevent and cure cancer through research, education and communication.

Jordan was the first scientist to demonstrate tamoxifen's ability to prevent breast cancer in laboratory rats. His pioneering work guided the evolution from preclinical lab studies to clinical research on the drug. He also was instrumental in the development of the estrogen-modulating compound raloxifene, originally approved for osteoporosis is postmenopausal women.

Jordan's published studies of tamoxifen and other "designer estrogens" have made him one of the top 20 most-cited breast cancer researchers over the past decade. He also recently received a $10.7 million grant from the Department of Defense Breast Cancer Research Program for a Breast Cancer Center of Excellence focused on developing a new treatment model for breast cancer to reverse the eventual development of resistance to anti-estrogen therapy.

His national and international awards include the General Motors Cancer Research Foundation's 2003 Charles F. Kettering Prize, the American Cancer Society's 2002 Medal of Honor, the 2001 Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research and the first Brinker International Breast Cancer Award for Basic Science from the Susan G. Komen Foundation in 1992. In 2002, Queen Elizabeth II named him an Officer of the Most Excellent Order of the British Empire (OBE) for services to international breast cancer research.

Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes nearly 26,000 basic, translational and clinical researchers; health-care professionals; and cancer survivors and advocates in the United States and more than 70 other countries. AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants.

Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, call 1-888-FOX CHASE or (1-888-369-2427).

More 2007 News Releases »